Clinical Trial Update: A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing bosutinib to imatinib in newly diagnosed chronic phase CML; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Leukemia Myelogenous Chronic Bcr-abl Positive

Drugs mentioned

• Bosutinib (bosutinib)
• Imatinib (imatinib)

Snippet

Sponsor: Pfizer | Conditions: Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive | Phase 3 | Status: COMPLETED | Results posted: 2018-11-14